A prospective, multicenter, randomised, double-blind, placebo-controlled, phase 3 study to compare the efficacy and the safety of masitinib versus placebo in the treatment of patients with severe uncontrolled asthma and elevated eosinophil levels
Latest Information Update: 11 Dec 2020
At a glance
- Drugs Masitinib (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors AB Science
- 07 Dec 2020 Status changed from active, no longer recruiting to completed.
- 20 Oct 2020 According to an AB Science media release, detailed results from this trial will be presented at an upcoming medical meeting.
- 20 Oct 2020 Results presented in an AB Science media release.